| Bioactivity | Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders[1][2][3][4]. | ||||||||||||
| Invitro | Aniracetam concentration-dependently counteracts glutsmate-, kainate-, or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced cell death and greatly facilitated neuroprotective response achieved by different concentrations of both quisqualate and trans-1-aminocyclopentane-1, 3-dicarboxylate in primary cultures of cerebellar granule cells[4].Aniracetam potentiates the mGluR-coupled stimulation of phospholipase C in primary cultures of cerebellar granule cells[4]. | ||||||||||||
| In Vivo | Aniracetam (1 mM; 30-75 min) potentiates the iQA receptors and produces remarkable facilitation of the native synaptic transmission in rats[1].Aniracetam (10-100 mg/kg; p.o.; single dosage) prevents the CO2-induced impairment of acquisition in rats[2].Aniracetam (30-300 mg/kg; p.o.; single dosage) increases the percentage of rats showing passive avoidance[2]. Animal Model: | ||||||||||||
| Name | Aniracetam | ||||||||||||
| CAS | 72432-10-1 | ||||||||||||
| Formula | C12H13NO3 | ||||||||||||
| Molar Mass | 219.24 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ito I, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43. [2]. Cumin R, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl). 1982;78(2):104-11. [3]. Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89. [4]. Pizzi M, et al. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem. 1993 Aug;61(2):683-9. [5]. Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. [6]. Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008 Apr;33(5):1071-83. Epub 2007 Jul 4. |